key: cord-0941867-nz06yohz authors: Nigar, Shireen; Shah, SM Tanjil; Setu, Md Ali Ahasan; Dip, Sourav Dutta; Ibnat, Habiba; Islam, M. Touhidul; Akter, Selina; Jahid, Iqbal Kabir; Hossain, M. Anwar title: Relative expression of proinflammatory molecules in COVID‐19 patients who manifested disease severities date: 2021-06-12 journal: J Med Virol DOI: 10.1002/jmv.27112 sha: a080d31b91bd2ed8496b809e190d95905cf8dfeb doc_id: 941867 cord_uid: nz06yohz Aggressive immune response, due to overexpressed proinflammatory molecules, has been characterized in coronavirus disease 2019 (COVID‐19) patients. Some of those mediators have a dual and opposite role on immune systems at play behind differential disease severities. We investigated the expression of some cytokines and chemokines in COVID‐19 patients in Bangladesh. We diagnosed the patients by detecting severe acute respiratory syndrome coronavirus 2 RNA in nasal swab samples by the real‐time RT‐PCR method. Thirty adult patients were preselected based on their disease severities and grouped into mild, moderate, and severe cases. Nine healthy volunteers participated in this study as a control. Relative expression of nine cytokines/chemokine in total leukocytes was semi‐quantified in SYBRgreen‐based real‐time quantitative reverse‐transcriptase polymerase chain reaction. We performed statistical tests on transformed log data using SPSS 24.0. At the onset of symptoms (Day 1), angiotensin‐converting enzyme 2 (ACE2) (p < 0.05) and interleukin (IL)‐6 (p > 0.05) were upregulated in all COVID‐19 groups, although the expression levels did not significantly correlate with disease severities. However, expressions of IL‐6, monocyte chemotactic protein‐1, macrophage inflammatory protein‐1α, tumor necrosis factor‐α (TNF‐α), RANTES (regulated upon activation, normal T cell expressed and secreted), and ACE2, on Day 14, were positively correlated with disease severities. Relative viral load at Day 1 showed no significant correlation with cytokine expression but had a significant positive correlation with RANTES and ACE2 expression on Day 14 (p < 0.05). Male patients had a higher level of IL‐6 than female patients on Day 1 (p < 0.05). All COVID‐19 patients showed upregulated cytokines and chemokines on Day 14 compared to Day 1 except TNF‐α. Female patients had a higher expression of ACE2 and IL‐12 on Day 14. Upregulated cytokines/chemokines at the convalescent stage, especially IL‐6, may help in targeting anticytokine therapy in post‐COVID‐19 patients' management. A novel coronavirus severe acute respiratory syndrome cor- The SARS-CoV-2 virus uses novel Metallo-carboxyl peptidase angiotensin receptor 2 (ACE2) to enter its human host cell. 10, 11 In spite of acting as the viral receptor, ACE2 protects against lung injury by degrading vasoconstrictive and proapoptotic protein. 12 ACE2 expressed higher in severe patients than mild and moderate. 13 The authors also found upregulation of several IFNs, cytokines, and immune-related genes for severe patients compared with mild and moderate patients. Biological sex variation influenced the severity of COVID-19 cases 14 as reported in various studies; men are more likely to get severe forms of COVID-19. [15] [16] [17] As cytokines and chemokines play a crucial role in the COVID-19 disease manifestations, theoretical therapeutic strategies should base on those. Several investigations have identified anticytokine therapies targeting overactive proinflammatory cytokines (IL-6 and TNF-α). Correct timing for administrating anticytokine therapies needs to recognize for COVID-19 patients' personalized treatment. Data on circulating viral mutants, disease manifestation to a specific population, relative expression, and comparative analysis of proinflammatory cytokine/chemokine in COVID-19 cases within a said geographical location is vital for making patients' management policy. Moreover, questions remained unanswered about the reasons for reduced severity and mortality in developing countries like Bangladesh. To the best of our knowledge, no data are currently available on cytokine expression either in Bangladesh or surrounding regions. We aimed in this study to explore the relationships between relative cytokine expression levels and disease severity, the effect of biological sex in clinical presentation or viral load at the nasopharynx swap of COVID-19 patients. We hope this work can predict therapeutic strategies in the developing south. The Ethical Review Committee of the Jashore University of Science and Technology approved this study (ERC No.: ERC/FBST/ JUST/2020-49). A total of 30 symptomatic COVID-19 patients were preselected, and patients were categorized into mild cases (n = 10), moderate cases (n = 10), and severe cases (n = 10) of COVID-19 according to the World Health Organization Guidelines for Diagnosis and Treatment of COVID-19 infection. 18 We performed detection of SARS-CoV-2 at the Genome Center, Jashore University of Science and Technology, Jashore, Bangladesh. We extracted viral RNA from a 10 µl clinical specimen (nasal swab and throat swab) within 12 h of specimen collection using Quick-Extract TM RNA extraction kit (Lucigen) following the manufacturer's instructions. Then, 10 µl of each viral RNA extract was amplified by one-step real-time quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) using a Novel Coronavirus Nucleic Acid Diagnostic Kit (Sansure Biotech Inc.). The kit detected n-and orf1b gene of SARS-CoV-2 and human RNase P gene as an internal control. In this study, samples with Ct values for both n-and orf1b genes of ≤35.0 were considered positive, that of >35.0 retested, and of >40.0 were considered negative. We used equation 2 −ΔCt to estimate viral load, where ΔCt = Ct viral N gene -Ct RNaseP . 19 We have translated all the data as log 10 (1 + 2 −ΔCt ). We collected approximately 4-5 ml of peripheral blood samples, within 24 h (Day 1) of laboratory confirmation of SARS-CoV-2 in nasopharyngeal swabs, from 30 COVID-19 symptomatic and 9 symptomatic patients. After 14 days, we collected blood samples from twenty patients with MIC (n = 10) and MOC (n = 10) symptoms from their residence while maintaining home quarantine. Three healthy volunteers (out of nine) tested SARS-CoV-2 positive during repeated sampling and were let off from the study. So we had six samples from healthy volunteers on Day 14. We could not collect blood samples from participants of the severe COVID-19 cases as they were either deceased after 14 days of initial sample collection or admitted into the ICU from whom we could not be allowed to collect the blood. We extracted total messenger RNA (mRNA) from human leukocytes using 1 ml of whole blood from all study participants using the SV total RNA isolation system (Promega), as per the manufacturer's instruction. According to the manufacturer's instructions, we prepared 20.0 µl complementary DNA (cDNA) from 8.0 µl of total mRNAs using the GoScript TM Reverse transcription system (Promega). We diluted 20 µl cDNA into a final volume of 100.0 µl. We performed SYBRgreen intercalation qRT-PCR to detect the expression level of two proinflammatory cytokines (TNF-α and IL-6), two antiviral cytokines (IFN-γ and IL-12), four chemokines (MIP-1α, RANTES, IP-10, and MCP-1), and ACE2. We used the primer sequences to detect these cytokines and chemokines from an earlier study. 20 The qRT-PCR was performed in QuantStudio TM 3 (Applied Biosystems), using the following protocol: denaturation at 95°C for 2 min followed by 40 cycles of 95°C for 10 s, annealing for 30 s, and All SC had respiratory failure and thus required ICU support. We recorded no death for mild and moderate groups but one death was reported during the study period in the SC group. 3.2 | Relative expression levels of cytokine and chemokine in studied participants 1 and 14. For any cytokine, different letters (a, b, c,) . indicates significant differences (p < 0.05). COVID-19, coronavirus disease 2019; RT-PCR, real-time reverse-transcriptase polymerase chain reaction discrimination for expression of MCP-1 and MIP-1α on Day 14. The relative expression level of IL-6 was higher (p < 0.05) in males on Day 1 but did not vary significantly (p > 0.05) with gender on Day 14. To our knowledge, this is the first study on cytokine/chemokine expression levels in COVID-19 patients in Bangladesh. We observed upregulation of ACE2 (p < 0.05) and IL-6 (p > 0.05) in MIC cases compared with HC on Day 1 (Figure 1 ). Many natural, common ways such as taking Vitamin C, Metformin, Vitamin B3, and Vitamin D can upregulate the ACE2 receptor. 22 Here in Bangladesh, doctors instructed COVID-19 patients to take Vitamin C and Vitamin B3 during their illnesses, increasing ACE2 expression. Although the virus uses ACE2 to enter into its host cell, upregulation of the cellular ACE2 receptor would likely be antiinflammatory and might have contributed to reduced mortality in COVID-19 patients. 22 Proinflammatory cytokines such as IL-6, TNF-α, while upregulated, trigger cytokine storms and ultimately lead to tissue damage and organ failure. 23 Although we observed a slightly increased expression of IL-6, we did not observe TNF-α upregulation at the onset of the disease ( Figure 1 ). Like our study, normal TNF-α levels were reported in COVID-19 patients by Wan et al. 24 However, elevated TNF-α levels in COVID-19 patients' sera were also reported recently. 4, 25 Recently some studies reported IL-6 as severity predictors of COVID-19. 26, 27 In a meta-analysis including 1426 patients, complicated COVID-19 patients had higher IL-6 expression levels (>3 times) compared with other uncomplicated patients. 28 In our study, COVID-19 patients had no higher expression of either IFN-γ or IL-12 than the HC group, which is indicative of the absence of elevated antiviral immune response at the onset of disease symptoms. Surprisingly, none of the cytokines and chemokines of ICU patients from the SC group shows significant differences compared with others. Zhang et al. 29 found that ICU patients in China had higher levels of IL-2R, IL-6, IL8, IL10, and TNF-α compared with reference ranges of the normal man. In other studies from Finland, ICU patients had higher levels of IL-6, C-reactive protein, and procalcitonin compared with non-ICU patients. 30 Keddie et al. 31 also noted similar findings. The authors demonstrated that CRP, IL-6, IL-10, and lactate dehydrogenase significantly correlated with ARDS and respiratory support. In another study, Lev et al. 32 also noted that IP-10 is associated with ICU patients and act as potential biomarkers. The combination of IL-6 × IL-10 serum levels has shown a predictor of ICU patients. 33 However, we observed differences in the expressions between studies. Recent work by Qin et al. 25 is also in accord with our observation, where COVID-19 severity was associated with increased levels of IL-6, IP-10, MCP-1, and MIP-1α. Although Costela-Ruiz et al. 7 reported elevated TNF-α and its association with severity in COVID-19 patients, we did not observe such differences. In another study, even the samples from nasopharyngeal swabs revealed the higher expression of IFN-γ and lowered expression of TGF-β1 and RANTES in symptomatic patients compared with negative patients. 39 But our studies demonstrated the higher expression of RANTES for MIC and MOC compared with HC. At the onset of the disease, the relative viral load had no significant correlation with cytokines and chemokines' relative expression ( Figure 3A ). However, initial viral load positively correlated with expression levels of IL-12, TNF-α, IL-6, RANTES, MIP-1α, and ACE-2, after 14 days. A higher level of IL-6 and RANTES decreased CD8 + T cell and virus. 40 The results from our study agreed with that study. In response to vaccinations, women induced a robust immune response. 41 In a previous study, estrogens lead to cytokine upregulation in mice treated with coronavirus. Estrogens had a protective role by suppressing the immune response's escalation phase. 42 As women are expressing more ACE2, therefore, less severity and death rate has been attributed in Bangladesh. A recent study showed that, compared with male patients, severe female patients had a greater IgG production level in weeks of the COVID-19 disease onset. 6 The protective role of IgG in female COVID-19 patients might be associated with the upregulation of IL-12. There were a few limitations due to the small sample size in our study. We could not collect repeated blood samples after 14 days from severe patients admitted to ICU. We also estimated the relative expression levels of cytokines and chemokines instead of serum cytokine levels. We could not collect samples from lungs and could not also target the cytokine expression in alveolar leukocytes. Modulators of cytokine expression released from the injured lungs may also spill and diffuse from the source to enter the systemic circulation, which might also contribute to significant upregulation of cytokine expression in the peripheral leukocytes and hence contributed to COVID-19 disease manifestations. However, live vaccines such as the BCG are known to induce trained immunity (enhanced innate immune response to subsequent infections). COVID-19 cases were reported as being lower in countries with universal BCG vaccination programs (such as Bangladesh, Nepal, Bhutan, Japan) compared to those without the programs (such as the United States, Spain, Canada, Italy). 43 We hypothesized that BCG vaccination might induce an immune response and reduce SARS-CoV-2 viremia and the severity of COVID-19 infections, 44 and cause rapid recovery of SARS-CoV-2 infection in the country. This study describes cytokine and chemokine expression among COVID-19 patients with different disease severity in a developing country, Bangladesh. We found that IL-6 could be targeted for anticytokine therapy here in Bangladesh. Although we could not prove any direct effect of BCG vaccinations on reduced severity of COVID-19, our data provide cytokine expression levels in BCG vaccinated COVID-19 patients. Knowledge of the underlying mechanisms of differential expressions and the associations of these cytokines with disease severity could help to target the choice for therapies. An interactive web-based dashboard to track COVID-19 in real time BCG vaccine protection from severe coronavirus disease 2019 (COVID-19) COVID-19: consider cytokine storm syndromes and immunosuppression Clinical features of patients infected with 2019 novel coronavirus in Wuhan Imbalanced host response to SARS-CoV-2 drives development of COVID-19 A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex SARS-CoV-2 infection: the role of cytokines in COVID-19 disease Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis Aging, male sex, obesity, and metabolic inflammation create the perfect storm for COVID-19 ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Angiotensin-(1-7)/mas inhibits apoptosis in alveolar epithelial cells through upregulation of MAP kinase phosphatase-2 Host transcriptomic profiling of COVID-19 patients with mild, moderate, and severe clinical outcomes Sex differences in severity and mortality among patients with COVID-19: evidence from pooled literature analysis and insights from integrated bioinformatic analysis Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis Transcriptional differences for COVID-19 Disease Map genes between males and females indicate a different basal immunophenotype relevant to the disease A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China Chemokine up-regulation in sarscoronavirus-infected, monocyte-derived human dendritic cells Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms Immunotherapeutic implications of IL-6 blockade for cytokine storm Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury Elevated interleukin-6 and severe COVID-19: a meta-analysis Correlation between cytokines and coagulation-related parameters in patients with coronavirus disease 2019 admitted to ICU IL-6 and other biomarkers as predictors of severity in COVID-19 Laboratory biomarkers associated with COVID-19 severity and management Observational cohort study of IP-10's potential as a biomarker to aid in inflammation regulation within a clinical decision support protocol for patients with severe COVID-19 A score combining early detection of cytokines accurately predicts COVID-19 severity and intensive care unit transfer Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily Altered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditions The amount of cytokinerelease defines different shades of Sars-Cov2 infection Interferon gamma, TGF-β1 and RANTES expression in upper airway samples from SARS-CoV-2 infected patients Disruption of the CCL5/RANTES-CCR5 pathway restores immune homeostasis and reduces plasma viral load in critical COVID-19 Sex differences in immunity. Seminars in Immunopathology The powerful immune system against powerful COVID-19: a hypothesis BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic Considering BCG vaccination to reduce the impact of COVID-19 The authors declare that there are no conflicts of interest.